全文获取类型
收费全文 | 1136篇 |
免费 | 5篇 |
专业分类
电工技术 | 4篇 |
综合类 | 1篇 |
化学工业 | 8篇 |
机械仪表 | 2篇 |
建筑科学 | 3篇 |
能源动力 | 1篇 |
轻工业 | 14篇 |
水利工程 | 1篇 |
一般工业技术 | 22篇 |
冶金工业 | 1042篇 |
原子能技术 | 3篇 |
自动化技术 | 40篇 |
出版年
2023年 | 3篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2018年 | 1篇 |
2017年 | 3篇 |
2016年 | 1篇 |
2015年 | 3篇 |
2014年 | 4篇 |
2013年 | 8篇 |
2012年 | 4篇 |
2011年 | 4篇 |
2010年 | 4篇 |
2009年 | 6篇 |
2008年 | 7篇 |
2007年 | 2篇 |
2006年 | 3篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2003年 | 9篇 |
2002年 | 8篇 |
2001年 | 6篇 |
2000年 | 7篇 |
1999年 | 36篇 |
1998年 | 300篇 |
1997年 | 169篇 |
1996年 | 119篇 |
1995年 | 81篇 |
1994年 | 52篇 |
1993年 | 55篇 |
1992年 | 9篇 |
1991年 | 23篇 |
1990年 | 20篇 |
1989年 | 21篇 |
1988年 | 21篇 |
1987年 | 15篇 |
1986年 | 24篇 |
1985年 | 12篇 |
1983年 | 1篇 |
1982年 | 9篇 |
1981年 | 3篇 |
1980年 | 9篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 13篇 |
1976年 | 41篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1967年 | 1篇 |
1964年 | 1篇 |
1955年 | 1篇 |
排序方式: 共有1141条查询结果,搜索用时 15 毫秒
21.
22.
Six adult patients with cleft palate, ranging in age from 47 to 78 years, were treated with self-tapping titanium implants. Twenty-three implants, 7 to 15 mm in length, were placed. Of these, one (4%) was 7 mm, eight (35%) were 10 mm, nine (39%) were 13 mm, and five (22%) were 15 mm. Time between stage I and stage II implant surgeries was 5 to 14 months, averaging 8.3 months. Time from stage II surgery to the present is 1.5 to 5 years, averaging 3 years. Of the 23 implants placed, 21 (91%) achieved osseointegration. One (4%) implant was not used prosthetically. Two (9%) 10 mm implants failed to integrate in one patient. All patients were treated with a maxillary complete denture or overdenture. Five (83%) required the addition of a pharyngeal section for speech enhancement. 相似文献
23.
24.
25.
KW Mahaffey CB Granger R Collins CM O'Connor EM Ohman SD Bleich JJ Col RM Califf 《Canadian Metallurgical Quarterly》1996,77(8):551-556
Intravenous heparin is routinely given after thrombolytic therapy for patients with acute myocardial infarction in the United States and in some, but by no means all, other countries. Several trials have documented improved infarct-artery patency in patients treated with heparin; however, none was large enough individually to assess the effect of heparin on clinical outcomes. We performed a systematic overview of the 6 randomized controlled trials (1,735 patients) to summarize the available data concerning the risks and benefits of intravenous heparin versus no heparin after thrombolytic therapy. Mortality before hospital discharge was 5.1% for patients allocated to intravenous heparin compared with 5.6% for controls (relative risk reduction of 9%, odds ratio 0.91, 95% confidence interval 0.59 to 1.39). Similar rates of recurrent ischemia and reinfarction were observed among those allocated to heparin therapy or control. The rates of total stroke, intracranial hemorrhage, and severe bleeding were similar in patients allocated to heparin; however, the risk of any severity of bleeding was significantly higher (22.7% vs 16.2%; odds ratio 1.55, 95% confidence interval 1.21 to 1.98). There was no significant difference in the observed effects of heparin between patients receiving tissue-type plasminogen activator and those receiving streptokinase or anisoylated plasminogen streptokinase activator complex, or between patients who did and did not receive aspirin. The findings of this overview demonstrate that insufficient clinical outcome data are available to support or to refute the routine use of intravenous heparin therapy after thrombolysis. It is not known if these findings are due to lack of statistical power, inappropriate levels of anticoagulation, or lack of benefit of intravenous heparin. Large randomized studies of heparin (and of new antithrombotic regimens) are needed to establish the role of such therapy. 相似文献
26.
While the osteopenia associated with oestrogen deficiency is thought to arise from a relative defect in bone formation with respect to resorption, oestrogen administration itself leads to a decrease, rather than an increase, in bone formation. This decrease in bone formation, which arises from oestrogen's inhibitory effect on bone turnover, presumably masks any underlying tendency of oestrogen treatment towards stimulation of bone formation. To investigate this further, we have examined the early effect of discontinuing the administration of oestradiol-17 beta (OE2; 40 micrograms/kg) on bone formation indices in ovariectomized 13-week-old rats, before the turnover-induced increase in formation occurs. Histomorphometric indices were assessed at the proximal tibial metaphysis 0, 7, 10, 13 and 16 days following discontinuation of OE2 treatment. Measurements of body weight, uterine weight and longitudinal growth rate confirmed that there were rapid effects of OE2 deficiency on these parameters. We could detect no significant increase in bone resorption, as measured by osteoclast surface and number, until 16 days after ending treatment with OE2; this was coincidental with a reduction in bone volume. Shorter periods of OE2 deficiency were associated with a marked decrease in bone formation, as assessed by dynamic histomorphometric indices. This inhibition of bone formation was largely due to a reduction in double fluorochrome-labeled trabecular surfaces, which were decreased by approximately 70%. We conclude that ending OE2 administration in ovariectomized rats caused a striking decrease in trabecular bone formation, if such indices are assessed prior to the subsequent turnover-induced increase in formation.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
27.
From 1970 to 1992 a total of 63 patients underwent operation for ampullary tumor: 40 pancreatoduodenectomies (PDs), 3 total PDs, 8 ampullectomies, and 12 bypass or exploratory laparotomies. The resectability rate was 68%. There were 9 benign tumors, 1 anaplastic tumor, and 53 adenocarcinomas. According to Martin's classification, there were 7 stage I, 11 stage II, 14 stage III, and 21 stage IV tumors. All patients with stage I, II, and III tumors underwent resection. Patients with stage IV tumors had either resection (n = 11) or bypass (n = 10). The mean duration of hospital stay was 20.6 days. Operative mortality was 12.7% for the whole series and 7.5% after PD (2.5% for the last 10 years). Overall survival was 40% at 5 years (85% for stage I, 65% for stage II, 44% for stage III, and 8% for stage IV). Survival was better for stages I, II, and III after PD than after ampullectomy. For stage IV patients survival was 70% after PD versus 20% after bypass at 1 year and 25% versus 0% after 2 years. In our opinion, PD should be proposed even for benign lesions because two of our patients had to undergo repeat operation (PD) 4 and 22 years later, respectively, for stage IV disease. PD is our choice for all tumors of the ampulla. 相似文献
28.
29.
A 66-year-old woman was admitted because of postmenopausal vaginal bleeding. Diagnostic workup revealed a poorly differentiated endometrial adenocarcinoma. A total abdominal hysterectomy and bilateral salpingo-oophorectomy was carried out (FIGO stage Ia, G3). One and a half years later she developed a solitary humeral metastasis which was treated by local radiotherapy and progesterone acetate. Because osseous metastases in endometrial adenocarcinoma are rare, the literature is reviewed. In analogy to the treatment of pulmonary metastases the option of disarticulation of the patient's arm is discussed. 相似文献